
Quarterly report 2023-Q1
added 05-18-2023
Aptinyx Net Debt 2011-2026 | APTX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.8 M | -92 M | -141 M | -98.8 M | -151 M | -92.1 M | -16.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.2 M | -151 M | -89.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Assembly Biosciences
ASMB
|
-55.8 M | $ 28.46 | 3.45 % | $ 319 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 221.88 | -0.87 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Axsome Therapeutics
AXSM
|
-205 M | $ 156.92 | -1.23 % | $ 7.81 B | ||
|
Galera Therapeutics
GRTX
|
-19.8 M | - | -32.59 % | $ 7.61 M | ||
|
Pharming Group N.V.
PHAR
|
-43.5 M | $ 15.36 | -0.71 % | $ 7.59 B | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.37 | -4.2 % | $ 350 M | ||
|
Kamada Ltd.
KMDA
|
-70.2 M | $ 8.5 | -1.39 % | $ 260 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Benitec Biopharma
BNTC
|
-1.92 M | $ 10.98 | -4.52 % | $ 452 M | ||
|
Inventiva S.A.
IVA
|
-95.6 M | $ 5.78 | -4.3 % | $ 138 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Compugen Ltd.
CGEN
|
-5.05 M | $ 2.09 | -0.95 % | $ 195 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
-3.94 M | $ 1.21 | -3.97 % | $ 71.5 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
PainReform Ltd.
PRFX
|
-15.7 M | $ 2.28 | -0.44 % | $ 1.03 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Foghorn Therapeutics
FHTX
|
-39.6 M | $ 5.0 | 2.25 % | $ 315 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.4 | -3.68 % | $ 1.02 B | ||
|
BioMarin Pharmaceutical
BMRN
|
-1.3 B | $ 54.13 | -1.64 % | $ 10.4 B | ||
|
Curis
CRIS
|
-17 M | $ 0.77 | 1.89 % | $ 4.86 M | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.52 | -5.59 % | $ 178 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 7.7 | -5.87 % | $ 1.29 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 3.34 | -4.02 % | $ 116 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.24 | -2.97 % | $ 704 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.8 | -1.1 % | $ 120 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Cabaletta Bio
CABA
|
-188 M | $ 2.94 | -3.29 % | $ 3.43 M | ||
|
Iterum Therapeutics
ITRM
|
7.16 M | $ 0.16 | -5.45 % | $ 3.15 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M |